SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Translational Development Acquisition Corp. (TDAC) trades at a trailing P/E of 28.7. Trailing earnings yield is 3.49%. Graham Number is $9.18.
Criteria proven by this page:
- VALUE (60/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
- Trailing Earnings Yield 3.49% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TDAC
Valuation Multiples
P/E (TTM)28.7
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio-27.90
P/S Ratio0.00
EV/EBITDA-245.4
Per Share Data
EPS (TTM)$0.37
Book Value / Share$10.15
Revenue / Share$0.00
FCF / Share$0.37
Yields & Fair Value
Earnings Yield3.49%
Dividend Yield0.00%
Graham Number$9.18
SharesGrow IV$9.76 (-7.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-573.7 |
0.00 |
-1,833.75 |
0.00 |
- |
| 2023 |
-83.5 |
-0.14 |
-79.86 |
0.00 |
- |
| 2024 |
-570.9 |
6.60 |
0.24 |
38.04 |
0.31% |
| 2025 |
28.4 |
-0.01 |
-27.66 |
0.00 |
4.04% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-0.02 |
$0.00 |
$-70.66K |
- |
| 2023 |
$-0.12 |
$0.00 |
$-485.55K |
- |
| 2024 |
$-0.21 |
$0.00 |
$-71.01K |
- |
| 2025 |
$0.37 |
$0.00 |
$6.36M |
- |
